Welcome to our dedicated page for Passage Bio news (Ticker: PASG), a resource for investors and traders seeking the latest updates and insights on Passage Bio stock.
Passage Bio, Inc. (NASDAQ: PASG) is a pioneering genetic medicines company dedicated to the development of transformative therapies for rare monogenic central nervous system (CNS) diseases. Leveraging cutting-edge gene therapy techniques, Passage Bio is advancing a robust pipeline aimed at addressing unmet medical needs in both pediatric and adult CNS disorders.
The company's key initiatives include the development of PBGM01 for infantile GM1 gangliosidosis, PBFT02 for frontotemporal dementia (FTD) caused by progranulin deficiency, and PBKR03 for infantile Krabbe disease. These therapies utilize proprietary adeno-associated virus (AAV) capsids to deliver functional genes directly to the brain and peripheral tissues, promising significant therapeutic benefits.
Passage Bio collaborates with leading institutions to bolster its research and development efforts. This includes a strategic research partnership with the University of Pennsylvania's Gene Therapy Program and a collaboration agreement with Catalent Maryland, Inc. Such alliances enhance Passage Bio's capacity to innovate and expedite the clinical development of its promising therapies.
Financially, Passage Bio is in a strong position, with a cash runway extending into the fourth quarter of 2025, allowing the company to diligently progress its clinical programs. Recent achievements include positive interim data from the Imagine-1 study, a Phase 1/2 clinical trial of PBGM01, demonstrating a favorable safety profile and initial evidence of efficacy in early and late infantile GM1 gangliosidosis.
Additionally, the company is making strides with PBFT02. Initial data from the upliFT-D clinical trial indicate promising safety and biomarker outcomes, showing elevated cerebrospinal fluid (CSF) progranulin levels. Such results underscore the potential of PBFT02 to address the underlying pathology of FTD and other neurodegenerative conditions.
Passage Bio is also committed to fostering the next generation of scientists through initiatives like the Tachi Yamada Scholarship program, which supports students in life sciences disciplines.
Passage Bio, Inc. (NASDAQ: PASG) announced that CEO Bruce Goldsmith will participate in a virtual panel at the 12th Annual Wedbush PacGrow Healthcare Virtual Conference, scheduled for August 10-12, 2021. Goldsmith's participation is set for August 11 at 8:35 a.m. ET. The event will be accessible via live webcast on the company's website, with a replay available for 30 days post-event. Passage Bio is dedicated to developing gene therapies for rare central nervous system disorders and has a collaboration with the University of Pennsylvania’s Gene Therapy Program.
Passage Bio (NASDAQ: PASG) will host a conference call on August 5, 2021, at 8:30 a.m. ET to discuss its second quarter 2021 financial results and recent business highlights. Investors can join the call by dialing 833-528-0605 (domestic) or 830-221-9711 (international), using conference ID 4037236. The call will also be available as a live audio webcast on the company’s website, with an archived version accessible for 30 days post-event. Passage Bio focuses on gene therapies for rare CNS disorders and collaborates with the University of Pennsylvania for its research.
Passage Bio, a clinical-stage genetic medicines company, granted an inducement award to its new Chief Commercial Officer, M. Maria Törnsén. This includes options to buy 200,000 shares at $13.04 each and 20,000 restricted stock units, vesting over four years. The award aligns with Nasdaq Rule 5635(c)(4) and aims to attract talent to advance therapies for rare CNS disorders. Passage Bio is focused on innovative gene therapies in partnership with the University of Pennsylvania's Gene Therapy Program to enhance its pipeline.
Passage Bio, Inc. (Nasdaq: PASG) has announced key leadership appointments, enhancing its capability in developing transformative therapies for rare CNS disorders. Effective immediately, Maria Törnsén takes on the role of Chief Commercial Officer, while Simona King will join as Chief Financial Officer on August 23, and Mark Forman, M.D., Ph.D. will assume the role of Chief Medical Officer on July 30. These appointments aim to bolster Passage Bio's pipeline and drive growth, positioning the company well for future clinical developments in gene therapy for patients in need.
Passage Bio (Nasdaq: PASG) announced the election of Dr. Derrell D. Porter to its Board of Directors and Audit Committee, effective May 27, 2021. Dr. Porter brings extensive experience in corporate strategy and product development from his leadership roles at Cellevolve Bio and Atara Biotherapeutics. His addition is expected to enhance the company's strategic direction in developing therapies for rare CNS disorders. Dr. Porter replaces Patrick Heron, who did not stand for re-election. The board aims to leverage Dr. Porter's expertise to strengthen commercial strategies for their gene therapies.
Passage Bio (NASDAQ: PASG) announced its participation in two virtual investor conferences in June 2021. The Jefferies Healthcare Conference will take place on June 2 at 4:30 p.m. ET, featuring a presentation format. On June 10, Passage Bio will engage in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference at 11:20 a.m. ET. Both events will be available via live webcast on the company's website, with replays accessible for 30 days post-event. As a clinical-stage genetic medicines firm, Passage Bio focuses on innovative therapies for rare CNS disorders.
Passage Bio (Nasdaq: PASG) announced a significant presentation by the University of Pennsylvania’s Gene Therapy Program at the ASGCT annual meeting, showcasing a new mouse model to evaluate gene therapy efficacy for metachromatic leukodystrophy (MLD). Preliminary results indicate that Passage Bio’s candidate PBML04 showed promising efficacy, reducing neurological deficits in this model. This advancement addresses the challenge of limited mouse models for MLD, facilitating the preclinical evaluation of AAV-mediated gene therapy. The company aims to advance its IND-enabling studies for PBML04.
Passage Bio (Nasdaq: PASG) will host its second virtual Research & Development event on May 17, 2021, focusing on frontotemporal dementia (FTD) with granulin mutations. This presentation will include robust pre-clinical data and insights into the clinical program for PBFT02, a gene therapy for FTD. Key speakers include Eliseo O. Salinas and Christian Hinderer, among others. The event will feature a Q&A session with prominent experts. The live webcast will be accessible on the company's website for 30 days after the event.
Passage Bio (NASDAQ: PASG) reported a net loss of $38.9 million for Q1 2021, with cash and equivalents at $437.6 million after a $166 million public offering. The company initiated its Phase 1/2 Imagine-1 trial for PBGM01, focused on infantile GM1 gangliosidosis, and expects the first patient for the FTD-GRN trial by 2Q/3Q 2021. Regulatory approvals were obtained for three advanced pipeline programs, including PBFT02 and PBKR03. Despite COVID-19-related delays, Passage Bio aims to reveal initial safety and biomarker data for its trials in 4Q21 and 1H22.
Passage Bio (NASDAQ: PASG) announced a collaboration with InformedDNA to offer no-cost genetic counseling and testing for adults diagnosed with Frontotemporal Dementia (FTD). The initiative aims to identify patients with inherited genetic mutations, facilitating early treatment and clinical trial recruitment. FTD affects 50,000–60,000 Americans and is a leading cause of dementia under age 65. Additionally, Passage Bio is developing PBFT02, a gene therapy for FTD with granulin mutations, which is slated for a Phase 1/2 clinical study.
FAQ
What is the current stock price of Passage Bio (PASG)?
What is the market cap of Passage Bio (PASG)?
What does Passage Bio, Inc. specialize in?
What are some of the key products in Passage Bio’s pipeline?
Who are Passage Bio’s key collaborators?
What is the focus of the Imagine-1 clinical study?
What recent advancements has Passage Bio made?
What is PBGM01?
What is the purpose of the Tachi Yamada Scholarship program?
When does Passage Bio expect to release additional data from their clinical trials?
What are the financial highlights of Passage Bio?
What is PBFT02 and what conditions does it target?
